Correlation between MP concentrations and markers of hemolysis/anemia in SCD patients.

<p>Correlation between MP concentrations and markers of hemolysis/anemia in SCD patients.</p

Biological and clinical characteristics of the SCD studied patients.

<p>Biological and clinical characteristics of the SCD studied patients.</p

Cellular origins and blood MP concentrations of SCA and HbSC patients.

<p>Cellular origins and blood MP concentrations of SCA and HbSC patients.</p

Comparison of total MP concentrations between not HC-treated SCA and HbSC patients classified according to the occurrence of VOC, ACS and abnormal TRJV.

<p><b>A</b>: Not HC-treated SCA children classified according to VOC, ACS and TRJV ≥ 2.5 m/s occurrences respectively. <b>B</b>: HbSC children classified according to VOC ACS and TRJV ≥ 2.5 m/s occurrences respectively. Blood total MP concentrations are represented as median with interquartile range.</p

Comparison of RBC- and PLT-derived MP characteristics between SCA and HbSC patients.

<p><b>A</b>: mean fluorescence intensity of annexin V; <b>B</b>: mean forward scatter index. The value distributions are represented as box and whiskers (min to max). ****: p < 10⁻⁴.</p

MP characterization by flow cytometry.

<p><b>A</b>: Acquisition gate (H) was based on forward- and side-scatter values of 0.9 mm-large calibration beads; <b>B</b>: autofluorescence was determined using isotopic control (IgG-PE); <b>C</b>: platelet-derived MPs or <b>D</b>: erythrocyte-derived MPs were labelled with FITC-annexin-V (FL1) and PE-conjugated monoclonal antibodies directed against CD41 or CD235a, respectively.</p